Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Eloralintide And Tirzepatide

EloraTZP

Stage Phase 3

Sponsor Eli Lilly and Company

Route injection

Sources

registry, as of 2026-11-03

https://clinicaltrials.gov/study/NCT07881432

A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 2115. Conditions Obesity. The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity. Participation in the study will last about 2 y

ClinicalTrials.gov NCT07881432 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT07881458

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1000. Conditions Obesity; Overweight; Diabetes Mellitus, Type 2. The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. Participation in the study will last abo

ClinicalTrials.gov NCT07881458 protocol and results modules

registry, as of 2026-01-30Stale

https://clinicaltrials.gov/study/NCT06916065

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 188. Conditions Overweight; Obesity. The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be

ClinicalTrials.gov NCT06916065 protocol and results modules

Studies

AMPLIFY-1

Registry NCT07881432

Phase Phase 3

Status Not yet recruiting

Enrollment 2115

EloraTZP Dose 1

Comparator placebo

Population Obesity

EloraTZP Dose 2

Comparator placebo

Population Obesity

EloraTZP Dose 3

Comparator placebo

Population Obesity

EloraTZP Dose 4

Comparator placebo

Population Obesity

EloraTZP Dose 5

Comparator placebo

Population Obesity

Tirzepatide

Comparator placebo

Population Obesity

Eloralintide

Comparator placebo

Population Obesity

Placebo

Population Obesity

AMPLIFY-2

Registry NCT07881458

Phase Phase 3

Status Recruiting

Enrollment 1000

Start 2026-10-16

EloraTZP

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Tirzepatide

Population Obesity; Overweight; Diabetes Mellitus, Type 2

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Registry NCT06916065

Phase Phase 1

Status Completed

Enrollment 188

Start 2025-04-09

Primary completion 2026-01-19

Study completion 2026-01-19

Catalyst Primary completion. 2026-01-19. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Eloralintide and Tirzepatide-Cohorts A-D

Regimen weekly

Weeks 26

Population Overweight; Obesity

Eloralintide-Cohorts E and F

Regimen weekly

Weeks 26

Population Overweight; Obesity